Skip to main content
    M

    Madrigal Pharmaceuticals Inc (MDGL)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $423.96
    -3.43 (-0.80%)

    Market Cap: $9.93B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Madrigal Pharmaceuticals Inc (MDGL) Valuation Multiples

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Madrigal Pharmaceuticals (MDGL) trades at 8.7x sales and 19.8x book value. Its P/B of 19.8x is above its 5-year median of 15.4x. Its forward P/E is 61.4x.

    Current Multiples

    MultipleValue
    P/E (trailing)N/A
    Forward P/E61.4x
    Price to sales8.7x
    Price to book19.8x
    PEGN/A
    FCF yield-1.4%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 157.1% above 7.7x.

    MultipleCurrent5-year median10-year median
    P/B19.8x15.4x7.7x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 120 months (10-year).

    Valuation History

    Over the 10 year ends shown, its P/B ranged from 3.4x in 2019 to 25.3x in 2022.

    Year endPriceP/SP/B
    2025$582.3415.8x21.7x
    2024$308.5737.4x9.0x
    2023$231.38N/A11.3x
    2022$290.25N/A25.3x
    2021$84.74N/A7.4x
    2020$111.17N/A7.2x
    2019$91.11N/A3.4x
    2018$112.72N/A3.6x
    2017$91.79N/A6.3x
    2016$14.90N/A4.7x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported.

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About MDGL

    What is MDGL's forward P/E ratio?

    Madrigal Pharmaceuticals has a forward P/E ratio of 61.4x.

    Is MDGL stock overvalued?

    GNG's valuation label for MDGL is Undervalued.

    What is MDGL's price to sales ratio?

    Madrigal Pharmaceuticals has a price to sales ratio of 8.7x.